Gilead Sciences (GILD)CFO sold ~$376K

~$376K

Approx. value · 3,000 sh @ $125.40

172K

Holds after · shares reported

Traded

Jun 15, 2026

Filed

Jun 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
2. Apr 15, 2026Insider · 2 peopleInsiders: 2 sales (~$846K)
3. Apr 28, 2026Insider · 1 personInsiders: 2 sales (~$1.3M)
4. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
5. Apr 30, 2026Layoff notice · 800 Bridge Parkway Redwood City CA 94065Layoff notice filed in CA: 108 employees
6. May 6, 2026Congress · 1 personMembers of Congress: 2 purchases
7. May 7, 2026Company filing · Form 8-K · ResultsReported its results
8. May 14, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
9. May 15, 2026Insider · 2 peopleInsiders: 5 sales (~$4.1M)
10. May 22, 2026FDAFDA drug approval: Hepcludex
11. May 22, 2026Government · Federal Register noticeNotice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
12. Jun 1, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
13. Jun 15, 2026 · this disclosureInsiderCFO sold ~$376K of GILD shares in the open market

What came next

1. Jun 15, 2026Insider · 1 personInsiders: 3 sales (~$372K)
2. Jun 24, 2026FDAFDA drug approval: Trodelvy
3. Jun 24, 2026FDAFDA drug approval: Trodelvy
4. Jul 1, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
5. Jul 15, 2026Insider · 2 peopleInsiders: 2 sales (~$780K)
6. Aug 3, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
7. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
8. Aug 17, 2026Insider · 2 peopleInsiders: 3 sales (~$4.3M)
9. Aug 20, 2026Insider · 1 personInsiders: 5 sales (~$725K)
10. Aug 26, 2026Insider · 1 personInsiders: 4 sales (~$2.7M)
11. Aug 27, 2026FDAFDA drug approval: Bixlenvo Sunlenca Starter Pack (Copackaged)
12. Aug 27, 2026FDAFDA drug approval: Sunlenca
13. Aug 27, 2026FDAFDA drug approval: Bixlenvo
14. Aug 27, 2026FDAFDA drug approval: Sunlenca
15. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
16. Sep 15, 2026Insider · 2 peopleInsiders: 4 sales (~$869K)
17. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$2.2M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 28 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 78 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Andrew D Dickinson, Chief Financial Officer

• SEC Form 4 at Gilead Sciences (GILD)Sep 16, 2026
• SEC Form 4 at Gilead Sciences (GILD)Aug 18, 2026
• SEC Form 4 at Gilead Sciences (GILD)Jul 16, 2026
• SEC Form 4 at Gilead Sciences (GILD)May 18, 2026
• SEC Form 4 at Gilead Sciences (GILD)Apr 16, 2026

The full history of Andrew D Dickinson, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Gilead Sciences

• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026

Everything OQRO holds on this company is on its GILD page.